Overview

This trial is active, not recruiting.

Conditions adult grade iii lymphomatoid granulomatosis, b-cell chronic lymphocytic leukemia, contiguous stage ii adult burkitt lymphoma, contiguous stage ii adult diffuse large cell lymphoma, contiguous stage ii adult diffuse mixed cell lymphoma, contiguous stage ii adult diffuse small cleaved cell lymphoma, contiguous stage ii adult immunoblastic large cell lymphoma, contiguous stage ii adult lymphoblastic lymphoma, contiguous stage ii grade 1 follicular lymphoma, contiguous stage ii grade 2 follicular lymphoma, contiguous stage ii grade 3 follicular lymphoma, contiguous stage ii mantle cell lymphoma, contiguous stage ii marginal zone lymphoma, contiguous stage ii small lymphocytic lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, noncontiguous stage ii adult burkitt lymphoma, noncontiguous stage ii adult diffuse large cell lymphoma, noncontiguous stage ii adult diffuse mixed cell lymphoma, noncontiguous stage ii adult diffuse small cleaved cell lymphoma, noncontiguous stage ii adult immunoblastic large cell lymphoma, noncontiguous stage ii adult lymphoblastic lymphoma, noncontiguous stage ii grade 1 follicular lymphoma, noncontiguous stage ii grade 2 follicular lymphoma, noncontiguous stage ii grade 3 follicular lymphoma, noncontiguous stage ii mantle cell lymphoma, noncontiguous stage ii marginal zone lymphoma, noncontiguous stage ii small lymphocytic lymphoma, progressive hairy cell leukemia, initial treatment, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, refractory hairy cell leukemia, refractory multiple myeloma, small intestine lymphoma, splenic marginal zone lymphoma, stage i adult burkitt lymphoma, stage i adult diffuse large cell lymphoma, stage i adult diffuse mixed cell lymphoma, stage i adult diffuse small cleaved cell lymphoma, stage i adult immunoblastic large cell lymphoma, stage i adult lymphoblastic lymphoma, stage i grade 1 follicular lymphoma, stage i grade 2 follicular lymphoma, stage i grade 3 follicular lymphoma, stage i mantle cell lymphoma, stage i marginal zone lymphoma, stage i multiple myeloma, stage i small lymphocytic lymphoma, stage ii multiple myeloma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii multiple myeloma, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv small lymphocytic lymphoma, untreated hairy cell leukemia, waldenström macroglobulinemia
Treatments bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
Target proteasome
Sponsor Barbara Ann Karmanos Cancer Institute
Collaborator National Cancer Institute (NCI)
Start date July 2011
End date June 2017
Trial size 20 participants
Trial identifier NCT02037256, 2008-134, NCI-2012-01173, P30CA022453

Summary

This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients. Giving chemotherapy before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
GROUP A: Patients receive filgrastim SC on days 1-9 and begin apheresis on day 5. Patients undergo apheresis for up to 2 days, and receive bortezomib intravenously (IV) over 3-5 seconds after target collection is obtained with filgrastim alone or on the first day of collection with the Bortezomib plus filgrastim mobilization, prior to receiving the administration of filgrastim. Second apheresis will continue until target stem cell dose is reached or for maximum 4 days. Patients undergo autologous hematopoietic stem cell transplantation after receiving high dose chemotherapy and peripheral blood stem cell (PBSC) infusion following standard of care procedures. GROUP B: Patients receive filgrastim SC on days 1-8 and receive bortezomib IV over 3-5 seconds on days 4 and day 7, before administration of filgrastim. Patients undergo apheresis on days 5-8. (See Detailed Description)
bortezomib LDP 341
Given IV
filgrastim G-CSF
Given SC
autologous hematopoietic stem cell transplantation
Undergo autologous hematopoietic stem cell transplantation

Primary Outcomes

Measure
Increase in levels of circulating PBSC by at least two-fold in the blood and in the apheresis collections in a 4-day collection protocol
time frame: Up to 6 months
Neutrophil engraftment
time frame: Up to 6 months

Secondary Outcomes

Measure
Co-mobilization of lymphoma or myeloma cells by bortezomib and filgrastim
time frame: Up to 6 months
Mobilization of dendritic cell subsets pDCI and pDC2 and the ratio DC1/DC2
time frame: Up to 6 months

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Voluntary written informed consent form before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care - Diagnosis of B-type NHL or with multiple myeloma and eligible for autologous transplantation - No more than 3 prior regimens of chemotherapy (Rituximab is not considered chemotherapy) and 4 weeks out of Bortezomib treatment for MM - Karnofsky performance status of > 50% - The patient has recovered from all acute toxic effects of prior chemotherapy - White blood cell (WBC) > 3.0 x 10^9/L - Absolute neutrophil count > 1.5 x 10^9/L - Platelet count > 100 x 10^9/L - Serum creatinine =< 2.2 - Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) less than two times the upper limit of normal (ULN) - Total bilirubin less than two times the ULN - Left ventricle ejection fraction > 50% (by normal echocardiogram [ECHO] or multi gated acquisition scan [MUGA] scan) - Diffusing capacity of the lung for carbon monoxide (DLCO) > 50% - Forced vital capacity > 50% of predicted - Negative for human immunodeficiency virus (HIV) - Female subject is either post-menopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential , agree to use 2 effective methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) from the time of signing the informed consent form through 30 days after the last dose of Bortezomib, or agree to completely abstain from heterosexual intercourse; women of child bearing potential agree to use an approved form of contraception; male subject, even if surgically sterilized (i.e., status post-vasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse for the duration of the study Exclusion Criteria: - Patient has a platelet count of < 100x 10^9/L within 14 days before enrollment - Patient has an absolute neutrophil count of ANC <1.5 x 10^9/L within 14 days before enrollment - Patient has creatinine of > 2.2 MG/DL within 14 days before enrollment - Patient has > 1.5 x ULN total bilirubin - Patient has >= grade 2 peripheral neuropathy within 14 days before enrollment - Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant - Patient has hypersensitivity to Bortezomib, boron or mannitol - Female subject is pregnant or breast-feeding; confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (b-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women - Participation in clinical trials with other investigational drugs not included in this trial, within 14 days before enrollment and throughout the duration of this trial - Serious medical or psychiatric illness likely to interfere with participation in this clinical study - A co-morbid condition which, in the view of the investigators, renders the patient at high risk for this study - An acute medical condition resulting from prior chemotherapy - Brain metastases or carcinomatous meningitis - Acute infection - Fever (temp > 38 degrees Celsius [C]/100.4 degrees Fahrenheit [F]) - Patients of child-bearing potential unwilling to implement adequate birth control - Patients who have deterioration of their clinical status or laboratory parameters between the time of enrollment and transplant (such that they no longer meet entry criteria) may be removed from study at the discretion of the treating physician or principal investigator - Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy - Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy

Additional Information

Official title A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients
Principal investigator Divaya Bhutani, M.D.
Description PRIMARY OBJECTIVES: I. To determine if addition of Bortezomib to the mobilization protocol will result with an increase in the levels of circulating peripheral blood stem cells (PBSCs) by >= 2-fold in blood and in the apheresis collections in up to 4-days collection protocol. II. To achieve median neutrophil engraftment of 12 days. SECONDARY OBJECTIVES: I. To test for co-mobilization of lymphoma or myeloma cells by bortezomib and G-CSF using real time polymerase chain reaction (PCR) for non-Hodgkin lymphoma (NHL) patients and by flow cytometry (cluster of differentiation [CD]38+/CD138+ cell) for multiple myeloma (MM) patients. II. To determine the effect of Bortezomib on the extent of mobilization of dendritic cells subsets, plasmacytoid dendritic cell (pDC)1 and pDC2 and DC1/DC2 ratio by flow cytometry. OUTLINE: Patients are assigned to 1 of 2 treatment groups. GROUP A: Patients receive filgrastim subcutaneously (SC) on days 1-9 and begin apheresis on day 5. Patients undergo apheresis for up to 2 days, and receive bortezomib intravenously (IV) over 3-5 seconds after target collection is obtained with filgrastim alone or on the first day of collection with the Bortezomib plus filgrastim mobilization, prior to receiving the administration of filgrastim. Second apheresis will continue until target stem cell dose is reached or for maximum 4 days. Patients undergo autologous hematopoietic stem cell transplantation after receiving high dose chemotherapy and peripheral blood stem cell (PBSC) infusion following standard of care procedures. GROUP B: Patients receive filgrastim SC on days 1-8 and receive bortezomib IV over 3-5 seconds on days 4 and day 7, before administration of filgrastim. Patients undergo apheresis on days 5-8. Within 2 months after mobilization, patients undergo autologous hematopoietic stem cell transplantation after receiving high dose chemotherapy and PBSC infusion as is the standard of care. After completion of study treatment, patients are followed at 1 month and 6 months.
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Barbara Ann Karmanos Cancer Institute.